- Home
- MIY vs CRDF Comparison
MIY vs CRDF Comparison
Compare MIY & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIY
- CRDF
- Stock Information
- Founded
- MIY 1992
- CRDF 1999
- Country
- MIY United States
- CRDF United States
- Employees
- MIY N/A
- CRDF N/A
- Industry
- MIY Investment Bankers/Brokers/Service
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MIY Finance
- CRDF Health Care
- Exchange
- MIY Nasdaq
- CRDF Nasdaq
- Market Cap
- MIY 340.0M
- CRDF 288.7M
- IPO Year
- MIY N/A
- CRDF N/A
- Fundamental
- Price
- MIY $11.49
- CRDF $3.05
- Analyst Decision
- MIY
- CRDF Strong Buy
- Analyst Count
- MIY 0
- CRDF 4
- Target Price
- MIY N/A
- CRDF $12.00
- AVG Volume (30 Days)
- MIY 56.8K
- CRDF 1.1M
- Earning Date
- MIY 01-01-0001
- CRDF 05-01-2025
- Dividend Yield
- MIY 3.98%
- CRDF N/A
- EPS Growth
- MIY N/A
- CRDF N/A
- EPS
- MIY N/A
- CRDF N/A
- Revenue
- MIY N/A
- CRDF $683,000.00
- Revenue This Year
- MIY N/A
- CRDF N/A
- Revenue Next Year
- MIY N/A
- CRDF N/A
- P/E Ratio
- MIY N/A
- CRDF N/A
- Revenue Growth
- MIY N/A
- CRDF 39.96
- 52 Week Low
- MIY $9.45
- CRDF $2.01
- 52 Week High
- MIY $11.70
- CRDF $6.38
- Technical
- Relative Strength Index (RSI)
- MIY 46.74
- CRDF 33.08
- Support Level
- MIY $11.23
- CRDF $3.65
- Resistance Level
- MIY $11.43
- CRDF $3.88
- Average True Range (ATR)
- MIY 0.08
- CRDF 0.20
- MACD
- MIY -0.01
- CRDF -0.08
- Stochastic Oscillator
- MIY 52.85
- CRDF 2.94
About MIY Blackrock MuniYield Michigan Quality Fund Inc.
Blackrock Muniyield Michigan Quality Fund Inc is a closed end fund. Its investment objective is to provide shareholders with as high a level of current income exempt from federal and Michigan income taxes.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").